Primary or secondary prevention for AD: Who cares?

The Lancet Neurology

Volumn 11, Issue 8, 2012, Pages 661-662

  Frisoni, Giovanni B ^a   Trojanowski, John Q ^b  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CRENEZUMAB; HYPOCHOLESTEROLEMIC AGENT; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; BRAIN AMYLOIDOSIS; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; HUMAN; LETTER; NERVE DEGENERATION; NEUROPATHOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION;

ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL; HUMANS; PRESENILINS;

EID: 84863875675     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70143-6     Document Type: Letter

References (5)

1. Colombia at the centre of preclinical AD research. Lancet Neurol 2012, 11:567. The Lancet Neurology.
2. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
3. Lee VM-Y, Brunden KR, Hutton M, Trojanowski JQ Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. The biology of Alzheimer's disease 2012, 455-474. Cold Spring Harbor Laboratory Press, NY, USA. D.J. Selkoe, D.M. Holtzman, E. Mandelkow (Eds.).
4. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007, 27:6174-6184.
5. Frisoni GB, Pievani M, Testa C, et al. The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 2007, 130:720-730.